Last reviewed · How we verify

NCT04982263

Blood Coagulation Abnormalities in COVID-19 (Corona Virus Disease-19) Patients

Completed Last updated 29 July 2021
What this trial tests

trial testing Blood coagulation profile in Covid19 in 125 participants. Completed in 31 May 2021.

Timeline
1 February 2021
Primary endpoint
31 May 2021
31 May 2021

Quick facts

Lead sponsorSohag University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment125
Start date1 February 2021
Primary completion31 May 2021
Estimated completion31 May 2021
Sites2 locations across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The role of the coagulation parameters in predicting the severity of COVID-19 disease will be assessed

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04982263.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing